Contrasting Graybug Vision (NASDAQ:GRAY) & Capstone (OTCMKTS:CAPS)

Earnings & Valuation

This table compares Graybug Vision and Capstone”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Graybug Vision	$426.96 million	0.00	-$35.60 million	($24.23)	-0.03
Capstone	$44.72 million	0.10	-$7.89 million	($0.95)	-0.58

Capstone has lower revenue, but higher earnings than Graybug Vision. Capstone is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Capstone has a beta of -1.21, meaning that its share price is 221% less volatile than the S&P 500.

Profitability

This table compares Graybug Vision and Capstone’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Graybug Vision	N/A	-77.61%	-71.34%
Capstone	N/A	N/A	N/A

Insider and Institutional Ownership

49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 2.5% of Capstone shares are held by institutional investors. 7.9% of Graybug Vision shares are held by company insiders. Comparatively, 59.1% of Capstone shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Capstone beats Graybug Vision on 6 of the 10 factors compared between the two stocks.

About Graybug Vision

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

About Capstone

Capstone Holding Corp., through its subsidiaries, engages in the distribution of masonry stone products in the United States. Its masonry stone products include manufactured and natural stone cladding products, natural stone landscape products and related goods for residential and commercial construction. The company was formerly known as Capstone Therapeutics Corp. and changed its name to Capstone Holding Corp. in February 2022. Capstone Holding Corp. was incorporated in 1987 and is headquartered in Tempe, Arizona. Capstone Holding Corp. operates as a subsidiary of BP Peptides, LLC.